A detailed history of Seeyond transactions in Seagen Inc. stock. As of the latest transaction made, Seeyond holds 14,342 shares of SGEN stock, worth $0. This represents 0.18% of its overall portfolio holdings.

Number of Shares
14,342
Previous 10,714 33.86%
Holding current value
$0
Previous $1.47 Million 25.8%
% of portfolio
0.18%
Previous 0.18%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$117.37 - $139.17 $425,818 - $504,908
3,628 Added 33.86%
14,342 $1.84 Million
Q3 2022

Nov 14, 2022

SELL
$135.27 - $180.11 $114,303 - $152,192
-845 Reduced 7.31%
10,714 $1.47 Million
Q2 2022

Aug 12, 2022

SELL
$108.81 - $179.33 $25,243 - $41,604
-232 Reduced 1.97%
11,559 $2.05 Million
Q1 2022

May 13, 2022

BUY
$119.61 - $157.85 $337,539 - $445,452
2,822 Added 31.46%
11,791 $1.7 Million
Q3 2021

Nov 12, 2021

SELL
$142.45 - $169.82 $12,962 - $15,453
-91 Reduced 1.0%
8,969 $1.52 Million
Q2 2021

Aug 13, 2021

BUY
$135.08 - $161.1 $5,403 - $6,444
40 Added 0.44%
9,060 $1.43 Million
Q1 2021

May 14, 2021

SELL
$137.51 - $190.8 $353,813 - $490,928
-2,573 Reduced 22.19%
9,020 $1.25 Million
Q4 2020

Feb 12, 2021

BUY
$164.63 - $211.93 $1.91 Million - $2.46 Million
11,593 New
11,593 $2.03 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Seeyond Portfolio

Follow Seeyond and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seeyond, based on Form 13F filings with the SEC.

News

Stay updated on Seeyond with notifications on news.